Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.

ABSTRACT:

Background

Utilization of alternative transcription start sites through alterations in epigenetic promoter regions causes reduced expression of immunogenic N-terminal peptides, which may facilitate immune evasion in early gastric cancer. We hypothesized that tumors with high alternate promoter utilization would be resistant to immune checkpoint inhibition in metastatic gastric cancer.

Patients and methods

Two cohorts of patients with metastatic gastric cancer treated with immunotherapy were analyzed. The first cohort (N = 24) included patients treated with either nivolumab or pembrolizumab. Alternate promoter utilization was measured using the NanoString® (NanoString Technologies, Seattle, WA, USA) platform on archival tissue samples. The second cohort was a phase II clinica

SUBMITTER: Sundar R 

PROVIDER: S-EPMC6442650 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature